First-line Doxorubicin for Advanced Sarcoma, Not Combo?

Share this post

Doxorubicin should remain first-line therapy for patients with soft-tissue sarcoma, conclude trialists who compared it with a gemcitabine and docetaxel combination.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply